



Vincenzo Di Lauro

Email: Email:



Phone: (+39)

Email: t Work permit: Italian Gender: Male



Phone: (+39)

Nationality: Italian

AREAS OF INTEREST

Breast and gynecological cancers, Rare tumors, Melanoma and Head and Neck cancers, Immunotherapy, Oncogenomics, Supportive therapy, Phase II, III and post-marketing clinical trials

WORK EXPERIENCE

[16/04/2021 – Current]

Medical Oncologist at Breast Oncology Division

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Address: Via Mariano Semmola, 52, 80131, Naples, Italy

Clinician at Breast Oncology Division c/o Breast and Thoracic Oncology Department

Chief: Prof. Michelino De Laurentiis

[01/10/2020 – 30/03/2021]

Medical Oncologist

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Address: Via Mariano Semmola, 52, 80131, Naples, Italy

Contract for the recruitment of clinicians at Breast Oncology Division c/o Breast and Thoracic Oncology Dept during COVID-19 emergency.

Chief: Prof. Michelino De Laurentiis

[13/11/2020 – 08/01/2021]

Medical Oncologist

Local Health Authority Naples 2 North, Health District 41

Address: Via Lupoli, 27, Frattamaggiore (NA).

Outpatient oncologist assignment at Frattamaggiore Presidium, Frattamaggiore (NA).

[13/04/2019 – 30/10/2020]

Medical Oncologist

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Address: Via Mariano Semmola, 52, 80131, Naples, Italy

Clinical assistance as medical oncology trainee and trial sub-investigator at Breast Oncology Division c/o Breast and Thoracic Oncology Dept

Chief: Prof. Michelino De Laurentiis

[02/11/2018 – 30/10/2020]

Clinical researcher

Università degli Studi di Napoli "Federico II"

Address: Via Sergio Pansini n. 5, 80131, Naples, Italy

Collaborator as a clinical researcher at the Regional Coordination Center for Rare Tumors (CRCTR) and the National Rare Tumor Network (RNTR)

Scientific Director: Prof. Sabino De Placido

[02/11/2015 – 30/10/2020]

Medical Oncology Trainee

Università degli Studi di Napoli "Federico II"

Address: Via Sergio Pansini n. 5, 80131, Naples

Specialization in Medical Oncology at the University Hospital “Federico II” of Naples, Department of Clinical Medicine and Surgery, Division of Medical Oncology

[07/2014 – 07/2015]

Medical Doctor (MD)

AOU - OO.RR. San Giovanni di Dio Ruggi d'Aragona - Scuola Medica Salernitana

Address: Via San Leonardo n. 1, 84131, Salerno, Italy

Internship at the University Hospital of “San Giovanni di Dio Ruggi d'Aragona”, Division of Oncology

Chief: Prof. Stefano Pepe

EDUCATION AND TRAINING

[07/07/2021 – 20/12/2022]

Advanced training course in Oncogenomics

University Hospital “Federico II” of Naples

Address: Via Sergio Pansini n. 5, 80131, Naples

[12/02/2022]

6th Master in Immuno-Oncology II' Level

NIBIT Foundation, Siena (IT)

[13/04/2019 – 30/10/2020]

Medical Oncology Trainee and trial sub-investigator at Breast Oncology Division c/o Breast and Thoracic Oncology Dept, Chief: Dr. Michelino De Laurentiis

Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”

Address: Via Mariano Semmola, 52, 80131, Naples, Italy

[02/11/2015 – 30/10/2020]

Specialization in Medical Oncology with a grade of 50/50 and honors at the University of Naples “Federico II”. Department of Oncohematology, Diagnostic Imaging and Forensic Medicine. Thesis title: “A Real-World Italian Experience about efficacy and clinical benefits of CDK 4/6 inhibitors in metastatic breast cancer”.

Università degli Studi di Napoli “Federico II”

Address: Via Sergio Pansini n. 5, 80131, Naples, Italy

[30/07/2020]

23rd Master in Immuno-Oncology I' Leve

NIBIT Foundation, Siena (IT)

[02/07/2018 – 31/07/2018]

Trainee at Breast Oncology Division c/o the National Cancer Institute “Fondazione G. Pascale”, within the training network provided by the School of Specialization in Medical Oncology of the University of Naples “Federico II”

Address: Via Sergio Pansini n. 5, 80131, Naples, Italy

[01/2012 – 06/2014]

Internship at the Medical Oncology Department of the University Hospital “San Giovanni di Dio Ruggi d'Aragona - Salerno Medical School” Chief: Prof. Stefano Pepe

Address: Via San Leonardo n. 1, 84131, Salerno, Italy

[21/03/2014]

Master's Degree in Medicine and Surgery with a grade of 110/110 at the University of Salerno, Faculty of Medicine and Surgery. Department of Medicine, Surgery and Dentistry “Scuola medica salernitana”. Thesis title: Analysis of a case series of head and neck cancers observed at the University Hospital “San Giovanni di Dio e Ruggi d'Aragona” during 2012-2013: a multidisciplinary model for global patient treatment.

Address: Via Salvador Allende n. 43, 84081, Baronissi (SA), Italy |

[05/07/2005]

Diploma with a grade of 100/100 from State High School Gymnasium “G.B. Vico”

Address: Piazza Cianciullo n.1, 84014, Nocera Inferiore (SA), Italy

NETWORKS AND MEMBERSHIPS

AIOM (Associazione Italiana di Oncologia Medica)
ESMO (European Society for Medical Oncology)
IGG (Italian Gem Cell Cancer Group)
SCITO (Società Campana di Immunoterapia oncologica)
GIM (Gruppo Italiano Mammella)

PUBLICATIONS

1. Management of hormone therapy-related toxicities in breast cancer patients.

Authors: Vincenzo Di Lauro, Michelino De Laurentiis | **Journal Name:** Civitas Hippocratica. Rivista bimestrale del Centro Studi di Medicina Salerno, January/April 2025.

2. PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescription.

Selected as poster at ESMO Breast Cancer 2025 (Monaco, 14-17 May, 2025)

Authors: Francesco Schettini, Giuseppe Di Grazia, **Vincenzo Di Lauro**, Morchón Araujo, Javier Calleja, David Pelegrina Sánchez, Benjamin Walbaum, Michela Palleschi, Antonino Musolino, Gaston Zatta Cobos, Assumpció López Paradís, Ona Cano i Cano, Aldo Caltavuturo, Sara Lopez-Tarruella Cobo, Michelino De Laurentiis, Grazia Arpino, Rodrigo Sanchez Bayona, César Augusto A. Rodríguez Sánchez, Tomás Pascual, Maria Jesus Vidal Losada

3. Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trial

Selected as poster at ESMO Breast Cancer 2025 (Monaco, 14-17 May, 2025)

Authors: Rossana Di Rienzo, Aldo Caltavuturo, Angela Grieco, Federica P. Mangiacotti, Alessandra Longobardi, Vincenza Cantile, Vittoria Molinaro, Pietro De Placido, Erica Pietroluongo, Vincenzo Di Lauro, Claudia Martinelli, Giuseppe Buono, Carmen Criscitiello, Giampaolo Bianchini, Lucia Del Mastro, Michelino De Laurentiis, Carmine De Angelis, Grazia Arpino, Mario Giuliano.

4. Social costs and quality of life in breast cancer patients enrolled in GIM30-RAPID: A prospective, observational, multicenter study evaluating the safety of real-life pertuzumab (P) and trastuzumab (T) fixed dose combination (FDC)

Selected as poster at ESMO Breast Cancer 2025 (Monaco, 14-17 May, 2025)

Authors: Giuseppe Buono, Michela Piezzo, Martina Pagliuca, Roberta Caputo, Francesco Nuzzo, Claudia Von Arx, Vincenzo Di Lauro, Francesca Carlino, Antonio Piccolo, Giorgia Pavone, Luigi Leo, Francesco Vitiello, Alessandra Fabi, Giuseppe Colantuoni, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi, Michele Orditura, Andrea Marcellusi, Michelino De Laurentiis

5. Association between CDK4/6 inhibitor (i) clinical outcomes and breast cancer (BC) histotypes

Selected as poster at ESMO Breast Cancer 2025 (Monaco, 14-17 May, 2025)

Authors: Claudia Von Arx, Claudia Martinelli, Claudia Calderaio, Annarita Verrazzo, Raffaella Di Monda, Rossana Di Rienzo, Margherita Tafuro, Vincenzo Di Lauro, Roberta Caputo, Ivana Cerillo, Miriam Pirolo, Annamaria Di Filippo, Stefania Cocco, Roberto Buonaiuto, Michela Piezzo, Michelino De Laurentiis

6. Insight on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.

Authors: De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, D'Esposito V, Poggio FB, Ruelle T, Cardinali B, **Di Lauro V**, Buono G, Caputo R, Buonaiuto R, Caltavuturo A, Rocco P, Porciello G, De Laurentiis M, Del Mastro L, Vernieri C, Veneziani BM, Bianco R, Crispo A, De Angelis C, Arpino G, Giuliano M. | **Journal Name:** Eur J Cancer. 2025 May; 221:115409

7. CAR-T cell therapy for breast cancer: Current status and future perspective.

Authors: Buono G, Capozzi M, Caputo R, Di Lauro V, Cianniello D, Piezzo M, Cocco S, Martinelli C, Verrazzo A, Tafuro M, Calderaio C, Calabrese A, Nuzzo F, Pagliuca M, Laurentiis M. | **Journal Name:** Cancer Treat Rev. 2025 Feb; 133:102868

8. Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.

Authors: Caltavitturo A, Buonaiuto R, Salomone F, Pecoraro G, Martorana F, Di Lauro V, Barchiesi G, Puglisi F, Del Mastro L, Montemurro F, Giuliano M, Arpino G, De Laurentiis M. | **Journal Name:** Crit Rev Oncol Hematol. 2025 Feb; 206:104577

9. The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options

Authors: Von Arx C, Calderaio C, Calabrese A, Marciano B, Martinelli C, Di Lauro V, Cerillo I, Cianniello D, De Laurentiis M. | **Journal Name:** Front Oncol. 2024 Dec; 14:1447508.

10. Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy

Authors: Scafuri L, Buonerba C, Di Lauro V, Tortora V, Cascella M, Liguori L, Sciarra A, Sabbatino F, Diana A, Marra A, Tarantino P, Trapani D, Giuliano M, Arpino G, Curigliano G, Di Lorenzo G. | **Journal Name:** Oncol Ther. 2024 Jun 28

11. Risposta mantenuta al trattamento di seconda linea con sacituzumab govitecan in paziente con malattia encefalica e sistemica da TNBC [Long-term response to second-line treatment with sacituzumab govitecan in a patient affected by brain disease and early relapsed TNBC]

Authors: Di Lauro V. | **Journal Name:** Recent Prog Med. 2024 Jun;115(6):31e-35e.

12. Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)

Selected as poster at ESMO Breast Cancer 2024 (Berlino, 15-17 May, 2024)

Authors: C. von Arx, A. Calabrese, R. Caputo, V. Di Lauro, M. Pensabene, G. Buono, A. Fabi, F. Cognetti, V. Guarneri, F. Puglisi, P. Vigneri, L. Del Mastro, G. Arpino, M. De Laurentiis

13. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study

Selected as poster at ESMO Congress 2023 (Madrid, 20-24 October, 2023)

Authors: Von Arx C, Calabrese C., Martinelli C., Di Lauro V., Grimaldi V., Pensabene M., Caputo R., Cerillo I., Cianniello D., Buono G., Verrazzo A., Pacilio C., Di Rella F., Nuzzo F., De Laurentiis M. | **Journal Name:** Annals of Oncology. 34. S370. 10.1016/j.annonc.2023.09.625

14. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion

Authors: Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M | **Journal Name:** Future Oncol 2023 Aug;19(24):1695-1708

15. Lung metastases

Authors: Vincenzo Di Lauro, Martina Pagliuca, Roberta Caputo | **Journal Name:** Metastatic breast cancer- Treatment and management 1st Edition (Paper/eBook) | **Editor:** Ed. Minerva Medica Maggio 2023

16. A case study of an elderly patient with bone metastasis from triple-negative breast cancer in response to first-line treatment with atezolizumab

Authors: Vincenzo Di Lauro, Michelino De Laurentiis | **Journal Name:** Breast Cancer Immunotherapy. *Raccolta di casi clinici nel carcinoma mammario triplo negativo. March 2023*

17. Case Report: Prophylactic use of Genedol to prevent aromatase inhibitor-induced arthralgia in patients with early breast cancer

Authors: Di Lauro Vincenzo, De Laurentiis Michelino | **Journal Name:** E-pub.Content Ed Net 2023

18. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Authors: V Di Lauro, G Barchiesi, F Martorana, G Zucchini, M Muratore, C Fontanella, G Arpino, L Del Mastro, M Giuliano, F Puglisi, M De Laurentiis | **Journal Name:** ESMO Open. 2022 Nov 15;7(6): 100629.

19. Triple negative breast cancer. A tissue microarray study of CXCR4 and correlation with microenvironment, P65, SRC, ERK, AKT

Selected as oral communication at the 9th SIAPeC-IAP Triennial Congress (Padova, 12-15 October, 2022)

Authors: G. Pannone, R. Barile, MC Pedicillo, C. Pizzulli, IS De Stefano, F. Collina, MR Brogna, D Iervolino, V Di Lauro, M Di Bonito.

20. Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

Authors: Giuseppe Buono, Grazia Arpino, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Fabio Puglisi, Alberto Zambelli, Saverio Cinieri, Francesco Nuzzo, Vincenzo Di Lauro, Paolo Vigneri, Giampaolo Bianchini, Filippo Montemurro et al. | **Journal Name:** Front Oncol. 2022 Oct 26;12:1032166.

21. Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis

Selected as poster at ESMO Congress 2022 (Paris, 09-13 September, 2022)

Authors: M. Pagliuca, L. Bencivenga, K. Komici, C. De Angelis, R. Caputo, F. Napolitano, D. Cianniello, V. Di Lauro, G. Rengo, S. de Placido, F. André, M. De Laurentiis

22. Case Report: Tolerability of adjuvant letrozole after tamoxifen therapy

Authors: Vincenzo Di Lauro, Michelino De Laurentiis | **Journal Name:** Clinical Point. Anno 9, N. 4, 2022. Volume 1. *Extended endocrine therapy with letrozole in breast cancer: clinical experiences of efficacy and tolerability*

23. Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review

Authors: Santorsola M, Di Lauro V, Nasti G, Caraglia M, Capuozzo M, Perri F, Cascella M, Misso G, Ottaiano A | **Journal Name:** Cancers (Basel). 2022 Jul 3;14(13):3262.

24. Case study: Adjuvant T-DM1 in a patient diagnosed with small tumor size and having a post-neoadjuvant residual disease

Authors: Vincenzo Di Lauro, Roberta Caputo | **Journal Name:** A novel (neo)adjuvant approach for HER2+ breast cancer in the non-metastatic phase. Suppl 1, June 2022.

25. CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): biological and clinical activity, and post-surgical approaches

Selected as poster at ESMO Breast Cancer 2022 (May 3-5, 2022)

Authors: S. Parola, V. Di Lauro, P. De Placido, V. Forestieri, G. Buono, C. von Arx, E. Pietroluongo, M. Pagliuca, D. Cianniello, R. Lauria, R. Caputo, G. Arpino, S. De Placido, M. Giuliano, M. De Laurentiis, C. De Angelis

26. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: a Real World Experience from a Cancer Center

Authors: Michela Piezzo, Roberta D'Aniello, Ilaria Avallone, Bruno Barba, Daniela Cianniello, Stefania Cocco, Antonio D'Avino, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco, Raffaele Piscitelli, Claudia von Arx, Michelino De Laurentiis, Piera Maiolino | **Journal Name:** *Pharmaceutics*. 2021 May 10;13(5):684.

27. Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

Selected as poster at ESMO Congress 2021 (16-21 September, 2021) and oral presentation at the XXIII AIOM National Congress 2021 (22-24 October, 2021)

Authors: Eva Blondeaux, Luca Boni, Tommaso Ruelle, Vincenzo Di Lauro, Chiara Molinelli, Michela Piezzo, Beatrice Fratini, Francesca Poggio, Palma Pugliese, Antonella Ferzi, Giulia Buzzatti, Stefania Russo, Ornella Garrone, Alessia D'Alonzo et al.

28. Case Study: Patient with oligometastatic breast cancer and durable complete response to first-line treatment with atezolizumab

Authors: Vincenzo Di Lauro, Roberta Caputo, Daniela Cianniello, Michela Piezzo, Michelino De Laurentiis | **Journal Name:** *Breast Cancer Immunotherapy. Collection of clinical cases in triple negative breast cancer*, April 2021.

29. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.

Authors: Diana A., Carlino F., Giunta E.F., Franzese E., Guerrera L.P., Di Lauro V., Ciardiello F., Daniele B., Orditura M. | **Journal Name:** *Curr. Treat. Options in Oncol.* 22, 45 (2021).

30. Folinic acid in colorectal cancer: esquire or fellow knight? Realworld results from a mono institutional, retrospective study

Authors: Francesco Jacopo Romano, Carmela Barbato, Maria Biglietto, Vincenzo Di Lauro, Dario Arundine, Roberto Fiorentino, Francesca Ambrosio, Maresa Cammarota, Bruno Chiurazzi, Livio Puglia, Sarah Scagliarini, Raffaella Ruocco, Carmen Mocerino et al. | **Journal Name:** *Oncotarget*. 2021 Feb 2;12(3):221-229.

31. Prospective observational study on the impact of OncotypeDX Breast Cancer Assay on treatment decisions and resources optimization in hormone receptor-positive/HER2-negative early breast cancer patients: preliminary results

Selected as oral presentation at SISMEC Intermediate Conference. November 12-13, 2020.

Authors: Piezzo M., Giuliano M., Milanese A., Paccosi S., Tanturli M., Vestri A., Cianniello D., Di Lauro V., De Laurentiis M.

32. Low-dose oral etoposide is an active option for patients with heavily pretreated thymic epithelial tumors

Selected as poster presentation at the XXII AIOM National Congress (30 October-1 November, 2020)

Authors: Ottaviano M., Tortora M., Giuliano M., Terracciano D., Dolce P., Di Lauro V., Picozzi F., Parola S., Riccio V., De Placido P., Pietroluongo E., Liotti A., La Civita E., Guggino G., Cicalese M., Curcio C., Longo M., Botti G., Daniele B. et al.

33. Targeting Autophagy in Breast Cancer

Authors: Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, Fusco G, Capozzi M, Gioia GD, Budillon A, De Laurentiis M. | **Journal Name:** *Int J Mol Sci.* 2020 Oct 22;21(21):E7836.

34. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

Authors: Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R et al. | **Journal Name:** *J Immunother Cancer.* 2020 Oct;8(2):e001154.

35. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Authors: Michela Piezzo, Stefania Cocco, Roberta Caputo, Daniela Cianniello, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco, Claudia Martinelli, Francesco Nuzzo, Matilde Pensabene, Michelino De Laurentiis | **Journal Name:** Int J Mol Sci. 2020 Sep 4;21(18):E6479.

36. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

Authors: Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, Iodice G, Nuzzo F, Pacilio C, Pensabene M, Laurentiis M. | **Journal Name:** Int J Mol Sci. 2020 Sep 3;21(17):E6400

37. Clinical implications of distinct immunoprofiles in patients with thymic epithelial tumors and autoimmunity

Selected as poster at ESMO Congress 2020

Authors: G. Palmieri, M. Giuliano, M. Tortora, P. Formisano, A.M. Malfitano, V. D'Esposito, G. Botti, A.L. Marretta, V. Margherita, V. Di Lauro, B. Daniele, S. De Placido, A. Verde, M. Ottaviano

38. Biomarkers in Triple-Negative Breast Cancer: State-of-the Art and Future Perspectives

Authors: S. Cocco, M. Piezzo, A. Calabrese, D. Cianniello, R. Caputo, V. Di Lauro, G. Fusco, G. di Gioia, M. Licenziato, M. De Laurentiis | **Journal Name:** Int J Mol Sci. 2020 Jun 27;21(13):E4579

39. Low-dose oral etoposide is an active option for patients with heavily pretreated thymic epithelial tumors

Selected as poster at ASCO Virtual Meeting 2020

Authors: Ottaviano M., Tortora M., Giuliano M., Terracciano D., Dolce P., Di Lauro V., Picozzi F., Parola S., Riccio V., De Placido P., Pietroluongo E., Liotti A., La Civita E., Guggino G., Cicalese M., Curcio C., Longo M., Botti G., Daniele B. et al. | **Journal Name:** J Clin Oncol 38, 2020 (suppl. abstr #9074)

40. Gosuran in combination with cyclin-dependent kinase inhibitors as first-line therapy in metastatic disease

Authors: Cianniello D, Caputo R, Di Lauro V, De Laurentiis M. | **Journal Name:** Expert Series. Real life experience in Oncology. Clinical cases. Anno 9, n. 10, 2019

41. Drug Cost Avoidance Retrospective Analysis resulting from treatment of patients with breast cancer in clinical trials.

Selected as oral presentation at the XL SIFO National Congress. Genoa, 21-24 November 2019

Authors: Maria Riemma, Michela Piezzo, Gaetano Buonfanti, Antonella Caporaso, Roberta Caputo, Daniela Cianniello, Stefania Cocco, Antonio D'Avino, Germira Di Gioia, Vincenzo Di Lauro, Giuseppina Fusco, Francesca D'Ambrosio, Marina Licenziato et al.

42. Oral Etoposide low dose in advanced refractory thymic epithelial tumors

Selected as oral presentation at the 10th International Congress ITMIG 2019 (10-12 October, 2019)

Authors: Palmieri G., Ottaviano M., Tortora M., Santomauro M.A., Di Lauro V., Picozzi F., Parola S., Riccio V., Mucci B., De Placido S., Giuliano M.

43. Insidious Fever in Thymoma Patient: A Very Challenging Diagnosis

Selected as poster at the 10th International Congress ITMIG 2019 (10-12 October, 2019)

Authors: M. Ottaviano, M. Giuliano, M. Tortora, R. Gallinoro, A. Buonomo, L. Catalano, B. Mucci, M. Santomauro, V. Di Lauro, V. Riccio, S. De Placido, G. Palmieri

44. Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour

Authors: Margaret Ottaviano, Chiara Maddalena, Maria D'Armiento, Rossella Lauria, Vincenzo D'Alessandro, Marianna Tortora, Elide Matano, Vincenzo Di Lauro, Brigitta Mucci,

45. Treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer: a real-world experience in a single Italian institution.

Selected as oral presentation at the 10th SISMEC National Congress. Rome, 18-21 September 2019

Authors: Piezzo M, Milanese A, Paccosi S, Simenon V, Tanturli M, Vestri A, Riemma M, Cianniello D, Caputo R, Cocco S, Di Lauro V, De Laurentiis M 1.

46. CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.

Authors: Piezzo M, Riemma M, Cianniello D, Caputo R, Fusco G, Di Gioia G, Cerillo I, Licenziato M, Buonfanti G, Cocco S, Di Lauro V, De Laurentiis M. | **Journal Name:** J Clin Oncol 37, 2019 (suppl; abstr e1253)

47. Clinical application of circulating cell-free DNA for monitoring the biological course of thymic epithelial tumors.

Selected as poster at ASCO Conference 2019 (31 May-04 June, 2019)

Authors: Margaret Ottaviano, Mario Giuliano, Marianna Tortora, Daniela Terracciano, Pietro Formisano, Antonietta Liotti, Nicoletta De Rosa, Gerardo Botti, Severo Campione, Stefania Staibano, Evelina La Civita, Carlo Curcio, Gianluca Guggino et al. | **Journal Name:** J Clin Oncol 37, 2019 (suppl; abstr #8566)

48. Anti EGFR-target therapy in advanced thymic epithelial tumors

Selected as poster at ASCO Conference 2019 (31 May-04 June, 2019)

Authors: Mario Giuliano, Margaret Ottaviano, Marianna Tortora, Roberta Gallinoro, Mirella Marino, Angela Pizzuti, Dario Arundine, Fernanda Picozzi, Vincenzo Di Lauro, Vittorio Riccio, Sabino De Placido, Giovannella Palmieri | **Journal Name:** J Clin Oncol 37, 2019 (suppl; abstr #8567)

49. A multidisciplinary model for the global treatment of Head and Neck Cancer

Poster at the "Pharmacy and Medicine Faculty Days 2014", Department of Pharmacy, University of Salerno, Fisciano Campus, 22-23 May 2014

Authors: Di Lauro V., Della Vittoria Scarpati G., Attianese MR., D'Antonio A., Pepe S.

- **ASCO Simultaneous Conference. Webinar, June 3-5, 2025**
Discussant
- **Communication and adherence to therapy in breast cancer: tools and strategies for effective treatment. Pompei, May 23-24, 2025**
Oral presentation: Management of CIN and NF prophylaxis in different chemotherapy regimens: guidelines vs. clinical practice.
- **SECOND MEDITERRANEAN CONFERENCE: EMBRACING CANCER IMMUNOTHERAPY. Naples, May 23, 2025**
Oral presentation: ADC in Breast Cancer
- **The Right Way...on Breast side! Naples, INT Pascale, 8-9 maggio 2025.**
Discussant
- **Management of issues related to endocrine therapy in breast cancer. 07 May 2025**
Training presentation
- **What's news in Breast Cancer Treatment Strategies. Termoli, April 29, 2025**
Oral presentation: How adjuvant treatment is changing in high-risk patients.
- **BREAST CANCER ADVANCED BOARD PROGRAMME 2025 Young healthcare professionals for younger patients. Rome, April 23, 2025**
Scientific director
- **Campania Onco Days on breast cancer. Day 1. Avellino, April 18, 2025**
Oral presentation: Role of CDK4/6 inhibitors: state of the art
- **B-restart 2025. Naples, April 2, 2025**
Scientific director
- **Question time: Q&A on HR+ early breast cancer. Mirabella Eclano (Bv), March 1, 2025**
Scientific director
- **Definition of treatment plan for patients with breast cancer from the early setting to the metastatic stage. Catania, February 8, 2025.**
Oral presentation: Update in Advanced Breast Cancer: HER2low
- **ADVANCED BREAST CANCER FOCUS ON LUMINAL DISEASE IN ELDERLY PATIENTS. Monocalzati (Av), January 31, 2025.**
Oral presentation: First-line treatment of luminal disease in elderly patients from clinical trials to real world, adherence and compliance to therapy.
- **"Supportive therapies in oncology". Caserta, January 16, 2025.**
Oral presentation: Management of side effects of aromatase inhibitors
- **Multidisciplinary Management of Breast Cancer. Naples, December 6-7, 2024**
Discussant
- **"BREAST CANCER 'mutated' - Focus on Early Stage". Avellino, December 6, 2024**
Oral presentation: Oncogenetic role and clinical implications of BRCA1/2 mutations.
- **Her2 low breast disease. November 25, 2024**
Training presentation
- **Onco Breast Academy 2024. Metastatic HER2+ breast cancer. Trani, November 16, 2024**
Scientific Director & Oral presentation: Therapeutic efficacy of new anti-HER2 drugs in brain disease.
- **BrEaST in practice@Campania&Puglia. Webinar, October 16, 2024.**
Oral presentation: Therapy management: sexuality and quality of life.

- **Breast Cancer Calabria I Edition. Magna Graecia University of Catanzaro. Catanzaro, October 11-12, 2024**
Oral presentation: Hot Topics Early Breast Cancer: New approaches to de-escalation and escalation

- **BREASTorming: Sharing the experience in early breast cancer (2nd Edition). Trani, September 27-28, 2025**
Scientific Director

- **MAXI-GUMM 5: Innovative Treatment Options for Endocrine Related Cancers (ERC) From mHSPC & Targeted Approaches in mCRPC to HER-2 Low & Triple Positive Breast Cancer: Redefining Clinical Settings. Assisi, September 24-25, 2024.**
Oral presentation: HER-2 and ER Crosstalking: Signaling Mechanisms and Clinical Implications

- **Gilead Preceptorship Residential Course. INT Pascale Naples, July 16-17, 2024**
Oral presentation: Future perspectives and combination strategies with monoclonal antibodies in HR+/HER2- disease.

- **Let's Talk About Breast Cancer. Naples, July 6, 2024**
Oral presentation: Optimization of therapy and improvement of tolerability: Presentation of a clinical scenario

- **Onco breast Academy 2024. Metastatic BC HER2 Low (HR+ and TNBC). Webinar July 1, 2024**
Scientific Director and Oral presentation: State of the art in the therapeutic algorithm of advanced HR+ disease

- **Breast in practice @Campania and @Puglia. Webinar, June 26, 2024.**
Oral presentation: Endocrine resistant patient – The expert's point of view

- **To Each His Own Treatment: Female Cancers and Personalized Treatments IV Edition. June 25, 2024**
Oral presentation: Treatment of Metastatic Her2+Breast Cancer

- **State of the art, Controversies, and Perspectives in Breast Cancer. Pompeii, June 21-22, 2024.**
Oral presentation: Genomic Testing in Choosing Adjuvant Treatment.

- **Early Breast Cancer Focus. Naples, June 17, 2024**
Oral presentation: Treatment of Patients with BRCA-Mutated Early Breast Cancer.

- **Breast Cancer Academy Meeting: Breast Cancer and Omics Profiling. Naples, June 12, 2024**
Oral presentation: Neoadjuvant Treatment in Breast Cancer: Difficult or Controversial Clinical Practice Situations.

- **Nausea & Vomiting Associated with Anticancer Treatment. Caserta, June 10, 2024**
Scientific Advisory Board.

- **What's more ? Updates in Breast Oncology. 2nd Meeting of Young Oncologists in Southern Italy (Puglia Edition). Bari, June 7-8, 2024**
Scientific Director

- **First Mediterranean Conference on open issues and new waves in immunotherapy and targeted therapy- to stay, to go away, to come back- Naples, May 24, 2024**
Oral presentation: The sooner the better: neoadjuvant or adjuvant? Triple negative and HER2 positive breast cancers

- **BrEaST in practice @Campania. Naples, May 23, 2024**
Scientific director and oral presentation: Updates on evidence for the patient with aBC HR+/HER2- and sharing of best practices.

- **B-restart 2024. Naples, May 21, 2024**
Scientific director

- **Oncology between Evolution and Revolution. Caserta, April 19, 2024**
Oral presentation: Brain metastases in HER2+ breast cancer: the dogma revolution.

- **AROMATease- Integrated management of aromatase inhibitor adverse events. Naples, April 16, 2024**
Scientific Advisory Board.
- **Immunotherapy in the treatment of non-metastatic triple-negative breast cancer. Naples, March 27, 2024**
Discussion of real-life clinical situations
- **Question time: Q&A on hormone-positive early breast cancer. Sorrento, March 9, 2024**
Scientific director
- **SCITO Annual Meeting- The Immunotherapy revolution from current knowledge to future perspectives. Naples, february 23, 2024**
Clinical cases discussion- outlier responses in breast cancer
- **SHER2low- Therapeutic scenario HER2low. Naples, february 19, 2024**
Scientific Advisory board
- **Multidisciplinary management of breast cancer 2023. Webinar, december 13-20, 2023**
Discussant
- **Breast cancer: Real Life and Scientific Update. Webinar, december 15, 2023**
Clinical case: Elderly patient at high risk
- **Prosigna Clinical Session – Sardinia. Virtual Meeting, November 29, 2023**
Oral presentation: Experience of the Pascale National Institute with Prosigna and genomic testing
- **Neoadjuvant therapy of triple-negative breast cancer. October 31, 2023**
Training presentation
- **Breast Talk: breast cancer and its surroundings. Bari, October 27, 2023**
Scientific director, provoker and speaker. Oral presentation: New opportunities: role of genomic signatures in risk definition
- **Onco Breast. From clinical trials to Real Word. Virtual meeting, October 18, 2023**
Scientific director. Lecture: Clinical trials. News from the scientific world.
- **Oncological therapies: yesterday...today & tomorrow 3.0. Capaccio Paestum, 13-14 October 2023**
Oral presentation: Management of the metastatic phase in the post-cycle setting: what is the positioning of the non-pegylated Liposomal Anthracycline
- **Seagen Round Table Breast Cancer. Pozzuoli, october 4, 2023**
Lecture: HER2CLIMB and recent tucatinib data overview
- **A life 2 change. State of art in the management of the patient with aBC HR+ HER2- Editorial project. Pozzuoli, September 20, 2023**
Lecture: Quality of life - an essential setting even in the metastatic setting
- **GIM Annual Meeting. Rome, september 15-16, 2023.**
Presenting GIM27 Therapy trial
- **Annual Meeting Genetic Oncology. Naples, september 6, 2023.**
Lecture: Optimal Management of Oncology Treatment Toxicity
- **Breastforming : Sharing the Experience in eBC. Tavola rotonda. Matera, July 14, 2023**
Scientific director
- **Work in progress: updating the therapeutic algorithms of metastatic luminal and triple negative breast cancer. Naples, July 5, 2023**
Oral presentation: Therapeutic scenario: Endocrine resistant disease with visceral involvement.
- **Metastatic Breast Cancer from Research to Clinical Practice. Centro Culturale Rivisondoli (AQ), June 29-30, 2023**
A case study: PARP Inhibitors: Current Affairs and Perspectives

- **OncoTable 2.0 Post ODX Decision Algorithm. Naples, June 21, 2023**
Oral presentation: Scientific Studies Update: TailorX 12 years/RxPONDER
- **Genomic profiling and biological classification in a efficient PDTA for a Breast Unit. Messina, June 20, 2023**
Oral presentation: The GEP experience at INT Pascale in clinical practice... the oncologist's point of view
- **New therapeutic scenarios for triple-negative breast cancer. Naples, June 13, 2023.**
Discussant: Clinical situations of patients treated with new anti-TROP2 ADCs
- **3rd CONGRESS OF THE TUSCAN SENOLOGY NETWORK. GENOMICS AND GENETICS IN BREAST CANCER. Cortona (AR), June 12-13, 2023**
Oral presentation: Genomic tests in the adjuvant treatment of breast cancer. The experience of Pascale National Institute in Naples
- **Multidisciplinarity in Oncology 2023. Roghudi (RC), 9-10 June 2023.**
Round Table: State of the art in the treatment of breast cancer
- **Focus on pharmacological and supportive therapy in patients with luminal breast cancer. INT Pascale Naples, June 9, 2023**
Oral presentations: The optimal duration of adjuvant endocrine therapy: why and when to propose extended therapy? & Management of adverse events related to endocrine therapy: improving compliance to improve results
- **Pathways in the management of patients affected by CTIBL. Naples, May 25, 2023**
Scientific Advisory board
- **Evolution in Oncology between today and tomorrow. Caserta, May 19, 2023.**
Oral presentation: Advanced HR+/HER2- Disease
- **Prosigna Clinical Session. Virtual Meeting. May 16, 2023.**
Oral presentation: Experience of INT Pascale Napoli with Prosigna
- **Update in Breast Cancer. Multigene Testing in Clinical Practice. Naples, May 05, 2023.**
A case study
- **What's more? Updates in Breast Oncology. 1st Meeting of Young Oncologists in Southern Italy (Sicily Edition). Palermo, April 28-29, 2023.**
Scientific Director
- **Hot Topics in Breast Cancer 1st Edition. Bari, April 22, 2023**
Lecture: BRCaM: when PARP inhibitors?
- **Perceptorship: Triple-negative breast cancer from research to clinical practice. INT Pascale Naples, April 17-18, 2023.**
Lecture: Re-Biopsy of metastatic disease: When and Why?
- **Breast Experience. Naples, February 9, 2023**
Scientific Advisory board
- **Therapeutic approaches to metastatic breast and ovarian cancer in the elderly patient. Avellino, November 25, 2022**
Oral presentation: Therapeutic algorithm and clinical management of elderly patient with metastatic triple negative disease: real-life experiences.
- **Therapeutic strategies in early-stage HER2-positive breast cancer. Naples, November 14, 2022**
A case study
- **GIM Annual Meeting. Naples, October 28-29, 2022.**
Updates on clinical studies and new proposals: GIM 22 ERIKA-GIM29 TUKAN (speaker)
- **Breast Cancer DOT-COM 2022. Ravello, October 7-8, 2022**
Oral presentation: Publication of a review on HR-QoL in Breast Cancer Patients with CDK4/6i: an example of successful experience from BC DOT-COM.

- **Global Virtual Preceptorship Program in Oncofertility. October 5, 2022.**
- **ABCDAY. Webinar. September 28, 2022.**
A case report: the pretreated elderly patient.
- **Post ASCO 2022 news in lung cancer and other neoplasms. Pascale National Institute (Naples), June 16, 2022**
Oral presentation: News in the breast cancer treatment
- **The treatment pathway of the patient with HR+HER2- breast cancer. Virtual Meeting, May 30, 2022.**
Oral presentation: Treatment options in the (neo)adjuvant setting
- **Therapeutic optimization of the patient with ER+/HER2- breast cancer. Forio d'Ischia, May 13-14, 2022.**
Oral presentation: CDK6/4 inhibitors in HR+/HER2- early breast cancer
- **Virtual Meeting Oncotable PUGLIA, SARDINIA, SICILY May 2, 2022**
Speaker
- **New generations compared in Advanced Breast Cancer HR+/HER2-. Salerno, March 18-19, 2022**
Oral presentation: Focus on radiotherapy: the oncologist and radiotherapist's point of view
- **EFFECTIVE TREATMENT OF ADVANCED BREAST CANCER AND PATIENT MANAGEMENT FOR DISEASE CONTROL". Naples, March 11-12, 2022**
Oral presentations: "CINV: how to improve the patient's quality of life" & "Endocrine therapy: between extension beyond 5 years and clinical practice (therapeutic adherence and management of side effects)"
- **Oncology Dialogues on CDK4/6 inhibitors: Treatment of Patients with Metastatic Breast Cancer HER+/HR+" Naples, December 17, 2021**
Oral presentation: Highlights in eBC and mBC on the Threshold of 2022
- **GIM Meeting. Padova, November 25-26, 2021.**
Oral presentation: Updates of GIM20 and GIM22 trials
- **Breast Life – journey through the care plan of the patient with mBC". Live Webinar, November 18-19, 2021**
Round Table
- **Breast cancer: a constantly evolving framework. Capaccio Paestum, 29-30 October 2021.**
Oral presentation: "Hormone therapy: when to extend adjuvant therapy"
- **Oncotype Dx Breast Recurrence Score test. June 15, 2021**
Scientific Advisory Board
- **Breast Talk 3rd Edition. Metastatic HR+/Her2- breast cancer. June 3, 2021**
Scientific Director
- **BreaST- Stay Tuned 2021. May 14, 2021**
Oral presentation: The treatment of advanced luminal-like breast cancers
- **Advances in the diagnosis of renal tumors. University of Naples "Federico II" (Naples), June 25, 2018**
A case study: Second-Line Treatments: How to Choose?

SKILLS

High level experience in national and international research trials; High level experience in genomic testing (Oncotype DX®, PAM50/ PROSIGNA®, EndoPredict, MammaPrint); High level experience in multidisciplinary groups and interdisciplinary committees for breast pathology and melanoma; Direct involvement in public prevention activities (outpatient visits and screening); Experience in HERHOME regional project for home oncological therapy; Computer skills: Adobe, Microsoft Office, Word, Excel, PowerPoint, Access; Ability to work in teams and independently; Excellent communication and leadership skills; Strong problem solving abilities; Great dedication to work.

**LANGUAGE
SKILLS**

Mother tongue(s): Italian

Other language(s):

English

WRITING C2

SPOKEN PRODUCTION C2

SPOKEN INTERACTION C2

French

WRITING B2

SPOKEN PRODUCTION B2

SPOKEN INTERACTION B2

Levels: A1 and A2: Basic user; B1 and B2:

Independent user; C1 and C2: Proficient user

**I authorize the processing of
personal data in accordance with
current legislation (Law 196/2003)
regarding privacy**

